Peanut challenges prior to oral immunotherapy demonstrate high tolerance rates in selected patients.

ABSTRACT:

Background

Peanut oral immunotherapy (pOIT) protocols typically remain below the threshold for reaction during the initial dose escalation (IDE) day. However, some patients may have higher thresholds for reaction or may not have an ongoing peanut allergy.

Objective

We sought to characterize the response to an accelerated initial dose escalation (A-IDE) for qualifying low-risk peanut-allergic patients younger than 4 years in which IDE progressed to a full peanut oral food challenge as tolerated.

Methods

Records of 76 pOIT patients younger than 4 years were reviewed. Those with history of peanut reaction with peanut allergy testing of less than 95% positive predictive value for failed oral food challenge were offered an A-IDE. A-IDE proceeded stepwise until patients ref

SUBMITTER: Gard CN 

PROVIDER: S-EPMC11978367 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature